Early intervention with therapeutic plasma exchange and intravenous immunoglobulinIntravenous immunoglobulin A therapy made from donated antibodies that may help reduce the mother’s immune response and protect the fetus. was essential in managing pregnancies complicated by RhD alloimmunizationAlloimmunization When a person’s immune system develops antibodies against foreign antigens from the same species—such as when an Rh-negative mother’s body forms antibodies against her baby’s Rh-positive red blood cells., according to a recent study published in Biomedical Research and Therapy.
Delayed or absent treatment could result in severe hemolytic disease of the fetus and newborn (HDFN), as illustrated by a 28-year-old RhD-negative mother who experienced repeated pregnancy losses. Timely administration of these therapies, particularly before 20 weeks of gestation, could significantly reduce fetal morbidity and mortality in sensitizedSensitization The process by which a mother’s immune system becomes “primed” to recognize and attack fetal red blood cells carrying incompatible antigens. pregnancies.
“Early identification of RhD negative pregnant women, coupled with timely detection of anti-D alloimmunization, regular monitoring of anti-D titres and fetal anemiaAnemia A condition that occurs when the body doesn’t have enough healthy red blood cells to carry oxygen to its tissues. In HDFN, anemia occurs when maternal antibodies destroy fetal red blood cells., and a multidisciplinary approach to managing HDFN due to anti-D alloimmunization, enhances the likelihood of a positive pregnancy outcome and fetal survival,” the authors of this study said.
This case highlighted the critical consequences of delayed treatment. The patient, previously sensitized during her second pregnancy, had high anti-D titers detected early in her third pregnancy. Despite initial follow-ups and plans for intervention, missed appointments and the lack of intrauterine transfusionIntrauterine transfusion A procedure that delivers donor red blood cells to the fetus through the umbilical vein to treat severe anemia caused by HDFN. facilities led to a tragic outcome. At 27 weeks, the patient delivered a macerated stillborn, underscoring the importance of continuous monitoring and access to specialized care.
Read more about prognosis of HDFN
The patient’s condition demonstrated a systemic gap in adhering to established guidelines for RhIGRho(D) immune globulin A preventive treatment that helps prevent Rh-negative mothers from developing antibodies that may harm the fetus. prophylaxis. During her first two pregnancies, she received only a single dose of RhIG at 28 weeks, with no postnatal prophylaxis. Proper adherence to protocols, including antenatal and postnatal prophylaxis, could have reduced the risk of alloimmunization from 16% to less than 0.2%. Early detection and regular follow-ups are also vital for managing high anti-D titers.
UltrasoundUltrasound An imaging test that uses sound waves to monitor fetal growth, development and signs of complications during pregnancy. assessments in her third pregnancy showed initial fetal health, with no severe signs of anemia despite elevated anti-D levels. However, the absence of timely therapeutic plasma exchange to lower antibodyAntibody A protein made by the immune system that recognizes and attacks foreign substances, such as bacteria, or in HDFN, fetal red blood cells carrying incompatible antigens. titers and inadequate follow-up care proved detrimental. This case underscored the need for accessible maternal-fetal medicine services and the early initiation of therapeutic plasma exchange and intravenous immunoglobulin in high-risk pregnancies.
Accessible care pathways, including counseling, timely RhIG prophylaxis, and consistent monitoring, are critical for preventing severe complications in sensitized pregnancies. This case reinforced the importance of healthcare systems ensuring early intervention and continuity of care to optimize outcomes for both mother and child.
